biotron limited (asx:bit) biotech showcase 2018...viral-encoded viroporin proteins • viroporins...
Post on 01-Jan-2021
4 Views
Preview:
TRANSCRIPT
BIOTRONLIMITED(ASX:BIT)BiotechShowcase2018
Forward Looking Statements
This presenta,onmay contain forward-looking statementswith respect to the financial condi,on, results andbusinessachievements/performanceofBiotronLimited(ACN086399144)andcertainoftheplansandobjec,vesof its management. These statements are statements that are not historical facts. Words such as “should”,“expects”, “an,cipates”, “es,mates”, “believes” or similar expressions, as they relate to Biotron Limited, areintended to iden,fy forward-looking statements. By their nature, forward-looking statements involve risk anduncertainty because they reflect Biotron’s current expecta,ons and assump,ons as to future events andcircumstancesthatmaynotproveaccurate.Thereisnoguaranteethattheexpectedevents,trendsorresultswillactuallyoccur.Any changes in suchassump,onsorexpecta,ons could causeactual results todiffermateriallyfromcurrentexpecta,ons.
BiotronLimited
• Biotron is designing, developing and commercialising a plaUorm ofan,viraldrugswithanovelmodeofac,on–abletotargetawidevarietyofviralinfec,ons
• Pipelineofprogramsinhighvalue,highneedmarkets• Progress in clinical leadprogram (BIT225) provides strong valida,on foren,replaUorm
BiotronLimited–SnapShot
BROADPLATFORMWITHNEWCLASSOFANTIVIRALDRUGS
HIV-1ERADICATION HBV&EARLYSTAGEPROGRAMSHEPATITISCVIRUS(HCV)
- Targe,ngHIV-1inlong-livedreservoirs
- Phase2trialinprogressduring2017;dosingcomplete
- NewclassofHCVdrug
- Phase2completed
- SeekingpartnershipsinChina
- Pipelineofearlystageprograms,including:
- Hepa,,sBvirus
- Respiratoryviruses
- Flaviviruses(Dengue)
ROBUSTCLINICALVALIDATION–COMPLETED8CLINICALTRIALSWITHSTRONGSAFETY&EFFICACYOUTCOMES
KeyAchievements2017
• CommencedPhase2HIV-1clinicaltrialofBIT225andCombina,onAn,retroviralTherapy(cART)inFeb’17
• DosingwithBIT225/placebocompleted;datapending(an,cipated1Q18)
• Demonstratedsignificantandacceleratedreduc,oninHIV-1viralloadfollowingaddi,onofBIT225inhumanisedmousemodelofHIV-1infec,oninFeb‘17
• IndependentNaturepublica,onvalidatedBiotron’sapproachoftarge,ngHIV-1inmacrophagesasakeystepinHIV-1eradica,oninMay’17
• AppointedaCorporateAdvisorforChina–assis,ngwithexecu,ngHCVregionalpartneringstrategyinJune‘17
• Raised$1.56millionviarightsissueinJune‘17
• Received$1.6millionR&DtaxrefundinNov‘17
HIV-1EradicaTonCurrentdrugsdonoteradicateHIV-1virus
WhyisHIV-1eradicaTonnecessary?• Long-termhealthimplica,onse.g.HAND,immuneac,va,on,drug-drug
interac,ons• Costoftreatment
• ~$20billionp.a.worldwide• Majorburdenonhealthcaresystems
BIT225haspotenTaltobeusedincombinaTonwithotherdrugsto
eradicateHIV-1reservoirs
• HIV-1remainshiddeninreservoirs,leadingtochronic,life-longinfec,on• Invisibletobody’simmunedefenses• Notsensi,vetoan,-HIV-1drugs
• Newmodeofac,onsdrugsareneededtoeradicateorcureHIV-1infec,on
MarioStevensonScien.ficAmerican299,78-83(2008)
CurrentDrugsDoNotEradicateHIV-1
MacrophagesareKeyHIV-1Reservoirs
StudypublishedinNatureMedicineinApril2017confirmedthatmacrophagesarekeyviralreservoirs
• BIT225inhibitsassemblyandbuddingofnewvirusinmacrophagereservoirs
• Phase1b/2atrial(004)demonstratedthatBIT225canreduceHIV-1levelsinmacrophagecellsinvivo,parallelinginvitrostudies(Wilkinsonetal,JAn,microbChemother.2015)
• Phase2trial(009)inprogress(BIT225incombina,onwithART)during2017
BIT225TargetsHIV-1inReservoirCells
A B
(A)UntreatedControls (B)BIT225treatedcells
BIT225–ProvenClinicalAcTvityAgainstHIV-1• BIT225-004:Phase1b/2arandomised,placebocontrolled,double-
blindtrial– 21pa,ents,HIV-1posi,ve,treatment-naïve;10daysdosing
withBIT225(monotherapy)• ResultsdemonstratedthatBIT225:
1. TargetsHIV-1inbloodreservoircells,andsignificantlyreducesvirusinthesecells
2. Crossestheblood-brainbarrier,openingupthepossibilityoftreatmentofAIDS-relateddemenTa
2. Reducedmyeloid-specificimmuneacTvaTonmarkersduringtrial
2 4 6 8
10 12 14 16
5 10 15 20 25
HIV-1Re
plica,
on(p
g/20
0uL)
TimeinCo-culture(days)
BIT225Placebo
PotenTalroleforBIT225:- AddiTontocurrentARTtoeradicatekeyreservoirs,impacTngimmuneacTvaTon- Keycomponentofcure/eradicaTonstrategies
HIV-1EradicaTon:BIT225-009Trial
• 36HIV-1+ve,treatment-naïvesubjectscommencingART• Randomised2:1(drug:placebo)
BIT225orplaceboaddedtoART
• BIT225orplaceboaddedtoARTforfirst12weeksoftreatment• Read-out
• Impactonviruslevels;reduc,onofimmuneac,va,onmarkers• Fullyrecruited;completeddosingwithBIT225/placebo.AnTcipatedatain1Q18
Biotron–NewApproachtoAnT-ViralDrugDevelopment
• Coreexper,seisdesignanddevelopmentofanewclassofan,viraldrugstarge,ngviral-encodedviroporinproteins
• Viroporinsarepresentinwiderangeofviruses:Influenza(M2),HIV-1(Vpu),HCV(p7),DengueandWestNile(Mprotein),SARS(Eprotein)andothers
• BroadplaUorm:
• Rapid,proprietaryprimarybacterialcell-basedscreeningassaysfortargetproteins
• Focusedlibraryofcompoundsthattargettheseviralproteins
• Pipelineofinternally-generated,first-in-classsmallmoleculeviroporininhibitorsforkeymarkets
Viroporins
• Smallhydrophobicproteinswithionchannelac,vity
• Formhydrophilicporesinhostcellmembranes
• Keystagesoftheviralcyclesuchasvirusuncoa,ng,transportandmatura,onareion-influencedprocessesinmanyviralspecies
• Crucialforviralpathogenicityduetoinvolvementinvariousstepsofviruslifecycles
• IdealtherapeuTctargets;exemplifiedbyBiotron’sHIV-1program(BIT225)
NatureReviewsMicrobiology10,563-574
UnlockingValueforOtherVirusTargets
Libraryofcompoundsdesignedtotargetviroporinsfoundinsomeviruses:Ini,ally>250compoundsdesignedandsynthesised;librarynow~350OTHER“HITS”INLIBRARYinclude:• InfluenzaAandB• Hepa,,sBvirus(HBV)• Coronaviruses(IncludingSARS)• Epstein-Barrvirus(EBV)• Zikavirus• Denguevirus• Herpesviruses• BKvirus
X-axis:compoundIDY-axis:virusZ-axis:strengthofhit
UnlockingValueforOtherVirusTargets
Biotron’sViroporinapproachenablesthetarge,ngofawiderangeofviraldiseases;examplesinclude:• RespiratoryVirusessuchasRespiratorySyncy,alVirus(RSV),Influenza,&Coronaviruses(leading
causeof“commoncold”)• FlavivirusessuchasZikaVirusandDengue• TransplantvirusessuchasBKvirus• EpsteinBarrvirus(EBV)-par,cularinterestinAsiawhereitiscausa,veagentofNasopharyngeal
Carcinoma Biotron’sViroporin-targeTngplahormhasthepotenTaltobecomeanimportanttoolin
thedevelopmentofanTviraltherapies
HepaTTsBVirusProgram• Hepa,,sBvirus(HBV)therapeu,cspacehassignificantinterestfrompharma&biotechcompanies
• ScreeningofBiotron’scompoundlibraryhasiden,fiedseveralcompoundswithac,vityagainstHBV
• ScreeninginHepG2andAD38celllines,aswellasstudiesinprimaryhumanhepatocytes(PHH)
• InvitrodataincludesevidenceofreducTonofindustryrecognisedmarkers,includingcccDNA
• Biotroncompoundsappeartohaveanovelmechanismofac,on• Poten,alforuseincombina,onapproachestotreatmentofHBV
• ExpandsBiotron’spartneringopportuni,es–poten,alforearlystageco-development/collabora,onagreement
DengueVirusProgram
• 2.5billionpeople(40%worldpopula,on)liveinareasatriskofDengue
• ~100millionpeopleinfectedyearly
• Aleadingcauseofillnessanddeathintropicsandsubtropics
• Transmissionisbymosquito;mostpreven,onprogramstargetthevector
• NoapprovedDengue-specifictherapeu,cdrug
• Vaccinetrialshavehaddisappoin,ngresults
• Biotronistarge,ngDengueMprotein–SimilartargettoHIV-1/VpuandHCV/p7
• Severalcompoundswithpromisingac,vityhavebeengenerated;testsareon-going
• Poten,alforpan-Flavivirustherapeu,c
www.sciencenews.org
HCV–RemainsanOpportunity
• ThenewHCVdrugsmaycausereac,va,onofHBVinHCV/HBVcoinfectedpa,ents
• ResultedinUSFDA“BlackBox”WarningonnewHCVdrugs
• 30millionHCV-infectedpeopleinChina,comparedto3-5millioninUSA
• 93millionchronicallyinfectedwithHBVinChina,comparedto2.2millioninUSA
• HighHCV/HBVco-infec,onrateinChina(es,matedtobe10million)
• Reac,va,onofHBVhaspoten,altobeamajorhealth&economicissueinChina
• BIT225hasbeenshowninclinicaltrialstosignificantlyimproveclinicaloutcomeinHCVGT1-infectedpa,entsincombina,onwithInterferon&Ribavirin(IFN/RBV)
• IFN/RBVhaveseveralpoten,aladvantagesovernewHCVdrugsinsomeseyngs
• IFN/RBVissignificantlycheaperthanthenewHCVdrugs
• HBVreac,va,onislesscommonandlesssevereinHCV/HBVco-infectedpa,entswithIFN/RBV
• SeekingpartnershipsforBiotron’sHCVprograminChina
CommercialisaTonandPartnering
• HIV-1Program-Significantvalueinflec,onpointsaroundHIV-1programdataexpectedin2018
• HCVProgram-BIT225par,cularlywellsuitedtoAsia,withhighnumbersofHCV-infectedpa,entsincludingahighpropor,onofHCV/HBVco-infectedpa,ents
• Earlystagecollabora,onopportuni,esforpre-clinicaltargets,suchas:
• Hepa,,sB
• Dengue
• Addi,onaldevelopmentcollabora,onpoten,alfor“other”pharmatargets
• Seekingpartnersforindividualtargetsoren,replaUorm
BoardMichaelHoy Non-execu,veChairman
MichelleMiller ManagingDirector
SusanPond Non-execu,veDirector
RobThomas Non-execu,veDirector
CorporateSnapshot
KeyFinancialMetricsTickerCode ASX:BIT
SharePrice(09Jan18) A$0.03
Marketcapitalisa,on A$11.4million
12MonthTradingRange A$0.016–0.046
SharesOutstanding 392million
CashPosi,on(09/2017) A$0.83million*
*ExcludesA$1.6mR&DtaxrebatereceivedinNov‘17
• SpunoutfromJohnCur,nSchoolofMedicalResearchattheAustralianNa,onalUniversityin1999
• ListedonASXinJan2001(ASX:BIT)
• HeadquarteredinSydney,Australia
BriefBiotronOverview
InvestmentHighlights
PorholioofpatentsandpatentapplicaTonsdirected to theCompany’s anT-viraldrugporholio
STRONGINTELLECTUALPROPERTYPOSITION
TargeTngviroporinproteinswitharapidscreeningproprietaryprimarybacterialcell-basedplahorm-alibraryofover350compoundswithacTvityagainstarangeofviruses.
NOVELANTIVIRALPLATFORM
ClinicalandPreclinicalprogramsinindicaTonswithhighunmetclinicalneedorlargepaTentpopulaTonssuchasHIV-1,HCV&Dengue,HBV,Zika&Influenza
BROADANTIVIRALPIPELINE
Completed7humanClinicalTrialswithpromisingsafetyandefficacyoutcomes
ROBUSTCLINICALVALIDATION
15 20
REPORT ANNUAL
BIOTRON
41
DrMichelleMillerManagingDirector+61412313329mmiller@biotron.com.auwww.biotron.com.au
top related